Shares of Rockwell Medical ($RMTI) surged more than 20% this morning after the company said the first of two planned Phase III studies for its experimental iron deficiency treatment hit its primary endpoint. The main goal in the study of SFP was a mean change in hemoglobin from baseline to end of treatment. The treatment also met key secondary endpoints, including maintenance of hemoglobin, maintenance of reticulocyte hemoglobin, and increase in serum iron pre- to post-treatment without an increase in ferritin. "These successful results, coupled with the recent positive PRIME study data demonstrating SFP's ability to significantly reduce ESA use, support our belief that SFP will set a new paradigm in iron therapy treatment for hemodialysis patients," said CEO Rob Chioini in a statement. "We believe SFP is positioned to become the new standard of care in iron therapy. We anticipate confirmatory and successful results from the CRUISE-2 trial, which is nearing completion." Release